{
    "Clinical Trial ID": "NCT00645333",
    "Intervention": [
        "INTERVENTION 1: ",
        "  MK-0752 and Docetaxel",
        "  MK-0752 in escalating doses, orally days 1-3, followed by docetaxel 80 mg/m2 IV on day 8, and pegfilgrastim 6mg SQ day 9. Cycle repeated every 21 days."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Men or women with metastatic (Stage IV) breast cancer, or with locally advanced breast cancer (Stages IIIA > 10 cm, or Stages IIIB and IIIC) that did not respond to first-line anthracycline-based chemotherapy, for whom docetaxel is a recommended therapy",
        "  Presence of measurable or evaluable disease",
        "  Adequate organ function",
        "  Ability to swallow intact study drug capsules",
        "  Zubrod Performance Status of 0-1 with at least a 3 month life expectancy",
        "  Appropriate time must have elapsed since prior anti-neoplastic therapy with resolution of acute toxicity",
        "Exclusion Criteria:",
        "  Concurrent treatment with hormonal therapy intended to treat cancer",
        "  Radiotherapy within 7 days prior to first dose",
        "  Symptomatic central nervous system, and/or epidural metastases or symptomatic carcinomatous meningitis or with radiation treatment completed within the past 8 weeks",
        "  Serious comorbid illness which will limit the ability of the patient to safely receive anticancer treatment",
        "  Patients who are pregnant or nursing",
        "  Confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Dose Limiting Toxicity (DLT)",
        "  The number of DLTs experienced by participants within the first 21 days.",
        "  DLTs were defined as toxicities possibly, probably, or definitely related to the study drug observed during the first 2 cycles (first 42 days) as follows:",
        "  Non-hematologic toxicity Grade 3 by the NCI CTCAE version 3.0.",
        "  ANC<1000 for more than 7 days despite use of pegfilgrastim.",
        "  Platelet count <25,000 for more than 7 days, or associated with bleeding, or less than 10,000 at any time.",
        "  Time frame: first 21 days",
        "Results 1: ",
        "  Arm/Group Title: MK-0752 and Docetaxel",
        "  Arm/Group Description: MK-0752 in escalating doses, orally days 1-3, followed by docetaxel 80 mg/m2 IV on day 8, and pegfilgrastim 6mg SQ day 9. Cycle repeated every 21 days.",
        "  Overall Number of Participants Analyzed: 30",
        "  Measure Type: Number",
        "  Unit of Measure: Dose Limiting Toxicities  5"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 16/30 (53.33%)",
        "  Chest pain *1/30 (3.33%)",
        "  Abdominal pain *1/30 (3.33%)",
        "  Diarrhea *2/30 (6.67%)",
        "  Edema limbs *1/30 (3.33%)",
        "  Hypersensitivity *2/30 (6.67%)",
        "  Autoimmune disorder *1/30 (3.33%)",
        "  Immune system disorder *1/30 (3.33%)",
        "  Device related infection *2/30 (6.67%)",
        "  Upper respiratory infection *1/30 (3.33%)",
        "  Fracture *1/30 (3.33%)"
    ]
}